Thymosin Alpha-1 (Tα1), also known as Thymalfasin, is a naturally occurring 28-amino acid peptide derived from the precursor protein prothymosin alpha. It is produced primarily by the thymus and plays an important role in regulating both the innate and adaptive immune systems.
Unlike many peptides promoted for wellness or regenerative medicine, Thymosin Alpha-1 has been extensively studied in human clinical trials for over three decades. Outside the United States, it has been approved in more than 35 countries for certain indications, including chronic hepatitis B, and has been investigated as an adjunctive therapy in viral infections, sepsis, cancer, immune deficiencies, and vaccine enhancement.
It is not FDA-approved for any indication in the United States.
Thymosin Alpha-1 functions primarily as an immunomodulatory peptide, helping regulate immune function rather than simply stimulating or suppressing immunity.
Research suggests Thymosin Alpha-1 may:
Unlike general immune stimulants, Thymosin Alpha-1 appears to help normalize immune responses, making it of interest in conditions characterized by immune dysfunction.
Clinical and preclinical studies suggest Thymosin Alpha-1 may provide several potential immunologic benefits.
Potential benefits include:
Although these findings are encouraging, many proposed applications remain investigational and additional high-quality randomized clinical trials are needed.
Thymosin Alpha-1 has generally demonstrated a favorable safety profile in published clinical trials.
Reported adverse effects include:
Because Thymosin Alpha-1 modifies immune function, caution should be exercised in individuals receiving immunosuppressive therapy or those with autoimmune diseases. Overall, published studies have reported relatively few serious adverse events compared with many immunomodulatory medications.
Thymosin Alpha-1 should generally be avoided or used only under specialist supervision in patients with:
Patients with complex immune disorders should consult an immunologist or other qualified healthcare provider before treatment.
United States
Thymosin Alpha-1 is not FDA-approved for any medical indication in the United States.
International Status
Synthetic Thymosin Alpha-1 (Thymalfasin; marketed internationally as Zadaxin®) has been approved in numerous countries for treatment of chronic hepatitis B and has been used clinically as an immune-modulating therapy in several additional conditions. Numerous clinical trials have evaluated its use in hepatitis C, sepsis, cancer, severe infections, vaccine enhancement, and immune deficiencies.
Human Studies
Thymosin Alpha-1 has one of the largest human evidence bases among peptide therapies.
Clinical trials have investigated its use in:
Many studies report improved immune markers and, in selected populations, improved clinical outcomes. However, evidence varies considerably by disease, and many indications remain investigational. Recent systematic reviews suggest potential benefit in selected patients with sepsis while emphasizing the need for larger multicenter trials.
Animal & Preclinical Studies
Animal and laboratory studies demonstrate that Thymosin Alpha-1 can:
These studies established the biologic rationale for subsequent human clinical development and continue to support investigation into additional therapeutic applications.
## Comprehensive Reviews
## Human Clinical Studies
Review Articles
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information.
Thymosin Alpha-1 is not FDA-approved for any medical indication in the United States. Although it is approved in several other countries for selected clinical indications and has been extensively studied in human trials, many proposed uses remain investigational. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# GHK-Cu (Copper Tripeptide)